Management of non-metastatic castrate-resistant prostate cancer: A systematic review

Yohann Loriot; Stéphane Supiot; Jean Baptiste Beauval; Friederike Schlürmann; Gilles Pasticier; Paul Sargos; Philippe Barthélémy; Géraldine Pignot; Denis Maillet; Sébastien Vincendeau; Emmanuel Gross; Guillaume Ploussard; Marc Olivier Timsit; Delphine Borchiellini

doi:10.1016/j.ctrv.2018.09.006

Management of non-metastatic castrate-resistant prostate cancer: A systematic review

Yohann Loriot, Stéphane Supiot, Jean Baptiste Beauval, Friederike Schlürmann, Gilles Pasticier, Paul Sargos, Philippe Barthélémy, Géraldine Pignot, Denis Maillet, Sébastien Vincendeau, Emmanuel Gross, Guillaume Ploussard, Marc Olivier Timsit, Delphine Borchiellini

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.

Original language	English
Pages (from-to)	223-231
Number of pages	9
Journal	Cancer Treatment Reviews
Volume	70
DOIs	https://doi.org/10.1016/j.ctrv.2018.09.006
Publication status	Published - 1 Nov 2018
Externally published	Yes

Keywords

Castration-resistant
Hormone therapies
Non-metastatic
Prostate cancer
nmCRPC

Access to Document

10.1016/j.ctrv.2018.09.006

Cite this

Loriot, Y., Supiot, S., Beauval, J. B., Schlürmann, F., Pasticier, G., Sargos, P., Barthélémy, P., Pignot, G., Maillet, D., Vincendeau, S., Gross, E., Ploussard, G., Timsit, M. O., & Borchiellini, D. (2018). Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews, 70, 223-231. https://doi.org/10.1016/j.ctrv.2018.09.006

@article{8d47b665aeeb4d8fb159a14b3636c178,

title = "Management of non-metastatic castrate-resistant prostate cancer: A systematic review",

abstract = "Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.",

keywords = "Castration-resistant, Hormone therapies, Non-metastatic, Prostate cancer, nmCRPC",

author = "Yohann Loriot and St{\'e}phane Supiot and Beauval, {Jean Baptiste} and Friederike Schl{\"u}rmann and Gilles Pasticier and Paul Sargos and Philippe Barth{\'e}l{\'e}my and G{\'e}raldine Pignot and Denis Maillet and S{\'e}bastien Vincendeau and Emmanuel Gross and Guillaume Ploussard and Timsit, {Marc Olivier} and Delphine Borchiellini",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = nov,

day = "1",

doi = "10.1016/j.ctrv.2018.09.006",

language = "English",

volume = "70",

pages = "223--231",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

}

TY - JOUR

T1 - Management of non-metastatic castrate-resistant prostate cancer

T2 - A systematic review

AU - Loriot, Yohann

AU - Supiot, Stéphane

AU - Beauval, Jean Baptiste

AU - Schlürmann, Friederike

AU - Pasticier, Gilles

AU - Sargos, Paul

AU - Barthélémy, Philippe

AU - Pignot, Géraldine

AU - Maillet, Denis

AU - Vincendeau, Sébastien

AU - Gross, Emmanuel

AU - Ploussard, Guillaume

AU - Timsit, Marc Olivier

AU - Borchiellini, Delphine

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.

AB - Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.

KW - Castration-resistant

KW - Hormone therapies

KW - Non-metastatic

KW - Prostate cancer

KW - nmCRPC

UR - http://www.scopus.com/inward/record.url?scp=85054458931&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.09.006

DO - 10.1016/j.ctrv.2018.09.006

M3 - Review article

C2 - 30300771

AN - SCOPUS:85054458931

SN - 0305-7372

VL - 70

SP - 223

EP - 231

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Management of non-metastatic castrate-resistant prostate cancer: A systematic review

Abstract

Keywords

Access to Document

Other files and links

Cite this